Research programme: receptor tyrosine protein kinase like orphan receptor inhibitors

Drug Profile

Research programme: receptor tyrosine protein kinase like orphan receptor inhibitors

Alternative Names: ROR1 inhibitors - Oncternal Therapeutics, Inc.

Latest Information Update: 06 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Oncternal Therapeutics, Inc.; University of California, San Diego
  • Class Antibodies; CAR-T cell therapies; Drug conjugates; Gene therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunologic cytotoxicity; Receptor protein-tyrosine kinase antagonists; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Jun 2016 Tokalas, Inc. has merged with Oncternal Therapeutics to form Oncternal Therapeutics, Inc.
  • 12 Apr 2016 University of California, San diego and Oncternal Therapeutics enter into a an exclusive worldwide license to develop and commercialise ROR1 inhibitors for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top